Clinical trials: Dyskinesias
Psychomotor Agitation, Schizophrenia
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.
- Conditions
- Psychomotor Agitation, Schizophrenia, Bipolar Disorder
- Trial name
- NCT04148963
- Testing
- Inhaled loxapine
- Volunteers
- 150 people
- Sponsor
- Lee's Pharmaceutical Limited
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Essential Tremor
The Efficacy of Aldehyde Dehydrogenase Enzyme in Essential Tremor Patients: A Single-Center Study
This is a sponsor-initiated, single-arm, single-center clinical trial designed to evaluate the efficacy and safety of an ALDH-containing food supplement (PICOZYME ET) in patients with Essential Tremor (ET).
- Trial name
- NCT07238725
- Testing
- PICOZYME ET
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Pico Entech Co., Ltd.
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 28 doses within a 12-week treatment period.
- Trial name
- NCT05271552
- Testing
- BXCL501
- Where
- 11 sites in United States
- Volunteers
- 151 people
- Sponsor
- BioXcel Therapeutics Inc
Spinocerebellar Ataxias
Stemchymal® for Polyglutamine Spinocerebellar Ataxia
The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design.
- Trial name
- NCT06397274
- Testing
- Stemchymal
- Volunteers
- 20 people
- Sponsor
- Steminent US, Inc.
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease
Escalating Dose Study in Healthy Volunteers With SEN0014196
This is a trial in healthy volunteers to study the safety, tolerability and pharmacokinetics of single and multiple escalating doses of SEN0014196.
- Trial name
- NCT01521832
- Testing
- SEN0014196
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Siena Biotech S.p.A.
Huntington Disease
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a first-in-human, non-randomized, phase I study in which participants with Huntington's Disease will receive three intravenous injections and will be followed…
- Trial name
- SAVE-DH (NCT02728115)
- Testing
- Cellavita HD Lower Dose, Cellavita HD Higher dose
- Where
- Brazil
- Volunteers
- 6 people
- Sponsor
- Azidus Brasil
PARKINSON DISEASE (Disorder)
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
- Trial name
- Vista PD (NCT07804615)
- Testing
- VIM0423
- Where
- 30 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Vima Therapeutics
Huntington's Disease
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months).
- Trial name
- NCT00387270
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medivation, Inc.
Huntington's Disease
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).
- Trial name
- NCT01485965
- Testing
- SEN0014196
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Siena Biotech S.p.A.
Alzheimer's Disease, Huntington's Disease
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
- Trial name
- NCT00975481
- Testing
- dimebon, alprazolam
- Volunteers
- 36 people
- Sponsor
- Pfizer
Ataxia Telangiectasia
Evaluate the Neurological Effects of EryDex on Subjects With A-T
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes)…
- Trial name
- NEAT (NCT06193200)
- Testing
- Dexamethasone sodium phosphate
- Where
- 19 sites in United States, Denmark and 7 more
- Volunteers
- 105 people
- Sponsor
- Quince Therapeutics S.p.A.
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Parkinson's Disease
The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
A randomized, double blind, placebo-controlled study employing a mixed parallel group and fixed sequence cross-over design. Patients will be randomized to one of two treatment groups ('E2007' or 'Placebo') in a 1:1 ratio and…
- Trial name
- NCT00451633
- Testing
- E2007
- Where
- 5 sites in Germany, Italy
- Sponsor
- Eisai Inc.
Tardive Dyskinesia
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyskinesia in subjects with schizophrenia or…
- Trial name
- NCT01393600
- Testing
- NBI-98854
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- Neurocrine Biosciences
Dystonia, Dystonic Disorder
Meditoxin® Treatment in Patients With Cervical Dystonia
To determine the efficacy and safety of Meditoxin in subjects with cervical dystonia compared with placebo (normal saline)
- Trial name
- NCT03232320
- Testing
- Meditoxin
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Medy-Tox
Dyskinesias, Parkinson's Disease
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.
- Conditions
- Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
- Trial name
- NCT00360568
- Testing
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube
- Where
- 22 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Huntington's Disease
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
- Trial name
- NCT07536061
- Testing
- SRP-1005
- Where
- 5 sites in Australia, New Zealand and 2 more
- Volunteers
- 32 people
- Sponsor
- Sarepta Therapeutics, Inc.
Dyskinesia, Parkinson's Disease
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with…
- Trial name
- LID in PD (NCT01767129)
- Testing
- AVP-923-45
- Where
- 3 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Avanir Pharmaceuticals